HighTower Advisors LLC Has $30.74 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

HighTower Advisors LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 113,857 shares of the biopharmaceutical company’s stock after selling 1,523 shares during the quarter. HighTower Advisors LLC owned 0.09% of Alnylam Pharmaceuticals worth $30,744,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the period. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Marshall Wace LLP increased its holdings in Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock valued at $89,100,000 after buying an additional 315,182 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 60.9% in the 4th quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company’s stock valued at $191,391,000 after buying an additional 307,702 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ ALNY opened at $442.73 on Friday. The company has a market capitalization of $58.03 billion, a P/E ratio of -179.24 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $445.20. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company’s 50 day moving average price is $342.13 and its 200-day moving average price is $289.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.13) EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the business’s stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. The trade was a 39.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 target price on the stock. Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a report on Monday, August 4th. UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a “buy” rating in a report on Friday, July 11th. Four analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $403.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.